The vaccine, called DNA-rTV, based on the replication of HIV DNA to stimulate an effective immunization, said Shao Yiming, a senior fellow HIV Control and Prevention CDC in China, adding that it is the first of this type of vaccine, which starts clinical trials of a second phase.
This developing a vaccine containing the DNA segments of the human immunodeficiency virus, and not the whole virus, it will have a strong and lasting effect. Shao said that he intended to deal with the types of HIV common in China.
Until now it was adopted more than 130 volunteers, and preparatory work is already under way in a hospital in Beijing, and the second – in Hangzhou (East), added to the document.
"We hope that we have finished the trial in the second half of 2021, and that by the end of the year we can begin the third phase, which involves thousands of volunteers to test the effectiveness of the vaccine," – said the expert.